Structure-based drug design with equivariant diffusion models

Arne Schneuing(École Polytechnique Fédérale de Lausanne), Charles B. Harris(University of Cambridge), Yuanqi Du(Cornell University), Kieran Didi(University of Cambridge), Arian R. Jamasb(University of Cambridge), Ilia Igashov(École Polytechnique Fédérale de Lausanne), Weitao Du(Academy of Mathematics and Systems Science), Carla P. Gomes(Cornell University), Tom L. Blundell(University of Cambridge), Píetro Lió(University of Cambridge), Max Welling(Microsoft (Netherlands)), Michael M. Bronstein(University of Oxford), Bruno E. Correia(École Polytechnique Fédérale de Lausanne)
Nature Computational Science
December 9, 2024
Cited by 155Open Access
Full Text

Abstract

Structure-based drug design (SBDD) aims to design small-molecule ligands that bind with high affinity and specificity to pre-determined protein targets. Generative SBDD methods leverage structural data of drugs with their protein targets to propose new drug candidates. However, most existing methods focus exclusively on bottom-up de novo design of compounds or tackle other drug development challenges with task-specific models. The latter requires curation of suitable datasets, careful engineering of the models and retraining from scratch for each task. Here we show how a single pretrained diffusion model can be applied to a broader range of problems, such as off-the-shelf property optimization, explicit negative design and partial molecular design with inpainting. We formulate SBDD as a three-dimensional conditional generation problem and present DiffSBDD, an SE(3)-equivariant diffusion model that generates novel ligands conditioned on protein pockets. Furthermore, we show how additional constraints can be used to improve the generated drug candidates according to a variety of computational metrics.


Related Papers